Grupp S, Maude S, Baruchel A, et al. Tisagenlecleucel appears effective and safe in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia with high-risk cytogenetic abnormalities. 24th Congress of EHA, abstract S1618.
Rituximab of obinutuzumab of plus CHOP bij nieuw-gediagnostiseerd DLBCL
aug 2017 | Lymfoom